‌

US Patent 8999331 Immunobinders directed against sclerostin

Patent 8999331 was granted and assigned to AbbVie Inc. on April, 2015 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Current Assignee

AbbVie Inc.

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

89993311

Patent Inventor Names

Wendy Waegell1

Yuliya Kutskova1

Alexander Ivanov1

Alyssa Brito1

Chung-Ming Hsieh1

Emma Fung1

Jacqueline Bixby1

John Memmott1

...

Date of Patent

April 7, 2015

Patent Application Number

136596471

Date Filed

October 24, 2012

Patent Citations Received

‌

US Patent 11999783 Method of treating autoimmune disease with antibodies against IL-33

Patent Primary Examiner

‌

Elizabeth C. Kemmerer

Patent abstract

Proteins that bind sclerostin or sclerostin and TNF are described along with there use in composition and methods for treating, preventing, and diagnosing sclerostin related diseases and for detecting sclerostin or sclerostin and TNF in cells, tissues, samples, and compositions.